Gene-focused biotechnology player Wuhan Binhui Biotech on Wednesday announced the completion of a 600 million yuan ($93 million) Series C round funding jointly led by healthcare-focussed Share Capital, Temasek’s Vertex Ventures China, Qianhai FOF, and CICC Capital’s sub-fund.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
